RU2016115726A - Селективный ингибитор фосфатидилинозитол-3-киназы-гамма - Google Patents
Селективный ингибитор фосфатидилинозитол-3-киназы-гамма Download PDFInfo
- Publication number
- RU2016115726A RU2016115726A RU2016115726A RU2016115726A RU2016115726A RU 2016115726 A RU2016115726 A RU 2016115726A RU 2016115726 A RU2016115726 A RU 2016115726A RU 2016115726 A RU2016115726 A RU 2016115726A RU 2016115726 A RU2016115726 A RU 2016115726A
- Authority
- RU
- Russia
- Prior art keywords
- disease
- pi3k
- compound
- biological sample
- composition containing
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 9
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 5
- 108091007960 PI3Ks Proteins 0.000 claims 5
- 102000001708 Protein Isoforms Human genes 0.000 claims 3
- 108010029485 Protein Isoforms Proteins 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 claims 2
- 101710096503 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (8)
1. Химическое соединение, имеющее следующую структурную формулу:
2. Фармацевтическая композиция, содержащая химическое соединение по п.1 и фармацевтически приемлемый носитель, адъювант или наполнитель.
3. Способ лечения или снижения тяжести заболевания или патологического состояния, выбранного из аутоиммунного заболевания или воспалительного заболевания, выбранного из астмы, атопического дерматита, ринита, аллергических заболеваний, хронической обструктивной болезни легких (ХОБЛ), септического шока, идиопатического легочного фиброза, инсульта, ожога, заболеваний суставов, ревматоидного артрита, системной красной волчанки, атеросклероза, острого панкреатита, псориаза, воспалительного заболевания кишечника, язвенного колита, болезни Крона и болезни Грейвcа, включающий в введение пациенту химического соединения или соли по п.1 или его фармацевтической композиции.
4. Способ по п.3, где указанное заболевание или патологическое состояние представляет собой ревматоидный артрит.
5. Способ ингибирования киназной активности PI3K-гамма в биологическом образце, включающий контактирование указанного биологического образца с соединением по п.1 или композицией, содержащей указанное соединение.
6. Способ селективного ингибирования изоформы PI3K-гамма по сравнению с, по меньшей мере, одной другой изоформой PI3K, включающий контактирование биологического образца с соединением по п.1 или композицией, содержащей указанное соединение или введение нуждающемуся в этом пациенту соединения по п.1 или композиции, содержащей указанное соединение.
7. Способ по п.6, в котором, по меньшей мере, одна другая изоформа PI3K выбрана из группы, состоящей из PI3K-альфа, PI3K-бета, PI3K-дельта и их комбинаций.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361882473P | 2013-09-25 | 2013-09-25 | |
| US61/882,473 | 2013-09-25 | ||
| PCT/US2014/057499 WO2015048318A1 (en) | 2013-09-25 | 2014-09-25 | A selective inhibitor of phosphatidylinositol 3-kinase-gamma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018142605A Division RU2018142605A (ru) | 2013-09-25 | 2014-09-25 | Селективный ингибитор фосфатидилинозитол-3-киназы-гамма |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016115726A true RU2016115726A (ru) | 2017-10-30 |
| RU2016115726A3 RU2016115726A3 (ru) | 2018-06-20 |
| RU2675814C2 RU2675814C2 (ru) | 2018-12-25 |
Family
ID=51795739
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018142605A RU2018142605A (ru) | 2013-09-25 | 2014-09-25 | Селективный ингибитор фосфатидилинозитол-3-киназы-гамма |
| RU2016115726A RU2675814C2 (ru) | 2013-09-25 | 2014-09-25 | 6,7-ДИГИДРО-5Н-ПИРРОЛО[3,4-b]ПИРИДИН-5-ОН, ПОЛЕЗНЫЙ В КАЧЕСТВЕ СЕЛЕКТИВНОГО ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ-ГАММА |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018142605A RU2018142605A (ru) | 2013-09-25 | 2014-09-25 | Селективный ингибитор фосфатидилинозитол-3-киназы-гамма |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10301304B2 (ru) |
| EP (2) | EP3412668B1 (ru) |
| JP (1) | JP6340416B2 (ru) |
| KR (1) | KR20160058950A (ru) |
| CN (1) | CN105722838B (ru) |
| AU (1) | AU2014324873B2 (ru) |
| BR (1) | BR112016006388A2 (ru) |
| CA (1) | CA2925601C (ru) |
| CL (1) | CL2016000695A1 (ru) |
| ES (2) | ES2785053T3 (ru) |
| HK (1) | HK1223620A1 (ru) |
| IL (1) | IL244742A0 (ru) |
| MX (1) | MX2016003823A (ru) |
| RU (2) | RU2018142605A (ru) |
| SG (2) | SG11201602265PA (ru) |
| UA (1) | UA117032C2 (ru) |
| WO (1) | WO2015048318A1 (ru) |
| ZA (1) | ZA201702252B (ru) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| BR112016007467B1 (pt) | 2013-10-04 | 2022-09-20 | Infinity Pharmaceuticals, Inc | Compostos heterocíclicos e usos dos mesmos |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN106456628A (zh) | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| JP6786529B2 (ja) * | 2015-06-29 | 2020-11-18 | バイオメッド バレー ディスカバリーズ，インコーポレイティド | Ｌｐｔ−７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 |
| MX2018003058A (es) | 2015-09-14 | 2018-08-01 | Infinity Pharmaceuticals Inc | Formas solidas de derivados de isoquinolinona, proceso de fabricacion, composiciones que las contienen y metodos de uso de las mismas. |
| WO2017153527A1 (en) * | 2016-03-10 | 2017-09-14 | Astrazeneca Ab | Novel inhibitors of phosphatidylinositol 3-kinase gamma |
| US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2020210379A1 (en) | 2019-04-10 | 2020-10-15 | Hangzhou Zhengxiang Pharmaceuticals Co., Ltd. | Phosphatidylinositol 3-kinase inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR071717A1 (es) * | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
| UY32582A (es) * | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| JP5721187B2 (ja) * | 2009-12-22 | 2015-05-20 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ホスファチジルイノシトール３−キナーゼのイソインドリノンインヒビター |
-
2014
- 2014-09-25 EP EP18180366.9A patent/EP3412668B1/en active Active
- 2014-09-25 RU RU2018142605A patent/RU2018142605A/ru unknown
- 2014-09-25 UA UAA201604461A patent/UA117032C2/uk unknown
- 2014-09-25 KR KR1020167010907A patent/KR20160058950A/ko not_active Application Discontinuation
- 2014-09-25 CN CN201480060785.XA patent/CN105722838B/zh not_active Expired - Fee Related
- 2014-09-25 CA CA2925601A patent/CA2925601C/en active Active
- 2014-09-25 RU RU2016115726A patent/RU2675814C2/ru not_active IP Right Cessation
- 2014-09-25 SG SG11201602265PA patent/SG11201602265PA/en unknown
- 2014-09-25 US US15/024,698 patent/US10301304B2/en active Active
- 2014-09-25 AU AU2014324873A patent/AU2014324873B2/en not_active Ceased
- 2014-09-25 ES ES18180366T patent/ES2785053T3/es active Active
- 2014-09-25 ES ES14789651.8T patent/ES2687593T3/es active Active
- 2014-09-25 BR BR112016006388A patent/BR112016006388A2/pt not_active Application Discontinuation
- 2014-09-25 SG SG10201802061TA patent/SG10201802061TA/en unknown
- 2014-09-25 MX MX2016003823A patent/MX2016003823A/es unknown
- 2014-09-25 JP JP2016516904A patent/JP6340416B2/ja not_active Expired - Fee Related
- 2014-09-25 EP EP14789651.8A patent/EP3049415B1/en active Active
- 2014-09-25 WO PCT/US2014/057499 patent/WO2015048318A1/en active Application Filing
-
2016
- 2016-03-23 IL IL244742A patent/IL244742A0/en unknown
- 2016-03-24 CL CL2016000695A patent/CL2016000695A1/es unknown
- 2016-10-17 HK HK16111963.2A patent/HK1223620A1/zh not_active IP Right Cessation
-
2017
- 2017-03-30 ZA ZA2017/02252A patent/ZA201702252B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2016000695A1 (es) | 2017-06-09 |
| EP3412668A2 (en) | 2018-12-12 |
| ES2687593T3 (es) | 2018-10-26 |
| SG11201602265PA (en) | 2016-04-28 |
| HK1223620A1 (zh) | 2017-08-04 |
| CN105722838B (zh) | 2017-10-24 |
| EP3049415B1 (en) | 2018-07-04 |
| UA117032C2 (uk) | 2018-06-11 |
| EP3412668B1 (en) | 2020-02-05 |
| JP2016531861A (ja) | 2016-10-13 |
| CN105722838A (zh) | 2016-06-29 |
| RU2675814C2 (ru) | 2018-12-25 |
| BR112016006388A2 (pt) | 2017-08-01 |
| RU2018142605A (ru) | 2019-02-04 |
| CA2925601C (en) | 2022-11-01 |
| ZA201702252B (en) | 2019-06-26 |
| CA2925601A1 (en) | 2015-04-02 |
| MX2016003823A (es) | 2016-08-01 |
| AU2014324873B2 (en) | 2018-11-08 |
| IL244742A0 (en) | 2016-04-21 |
| EP3049415A1 (en) | 2016-08-03 |
| US10301304B2 (en) | 2019-05-28 |
| EP3412668A3 (en) | 2018-12-19 |
| SG10201802061TA (en) | 2018-05-30 |
| WO2015048318A1 (en) | 2015-04-02 |
| US20160214980A1 (en) | 2016-07-28 |
| KR20160058950A (ko) | 2016-05-25 |
| RU2016115726A3 (ru) | 2018-06-20 |
| ES2785053T3 (es) | 2020-10-05 |
| JP6340416B2 (ja) | 2018-06-06 |
| AU2014324873A1 (en) | 2016-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016115726A (ru) | Селективный ингибитор фосфатидилинозитол-3-киназы-гамма | |
| JP2016531861A5 (ru) | ||
| BR112015017338A2 (pt) | anticorpos anti-il-17a e seu uso no tratamento de transtornos autoimunes e inflamatórios | |
| JP2011037847A5 (ru) | ||
| CL2013000391A1 (es) | Compuestos derivados de 6-(2-hidroximetil-fenil)-2-metil-2h-piridazin-3-ona, inhibidores de la tirosina-quinasa de bruton (btk); composicion farmaceutica; metodo para tratar una condicion inflamatoria y/o autoinmune, artritis reumatoidea o asma; y su uso para tratar una condicion inflamatoria y/o autoinmune. | |
| EA201590721A1 (ru) | Фармацевтические композиции, содержащие ингибитор pde4 и ингибитор pi3-дельта или двойной ингибитор pi3-дельта-гамма киназы | |
| RU2008118491A (ru) | Первичная кислая фосфатная соль антагониста рецептора простагландина d2 | |
| PH12015500294A1 (en) | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors | |
| NO20083568L (no) | Hydantoinforbindelser for behandling av inflammatoriske forstyrrelser | |
| WO2013048214A3 (en) | Novel heterocyclic derivatives and their uses | |
| NO20080125L (no) | 2,6-kinolinylderivater, fremgangsmater for fremstilling derav og deres anvendelse som medikament | |
| PH12015501994A1 (en) | Antibodies that bind il-23 | |
| RU2015139758A (ru) | Хиназолины в качестве ингибиторов киназы | |
| RU2015113587A (ru) | Амидное производное и его применение в качестве критерия стабильности фармацевтической композиции луликоназола | |
| JP2015505555A5 (ru) | ||
| JP2016530297A5 (ru) | ||
| RU2020102709A (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ ИНГИБИТОРАМИ С-С ХЕМОКИНОВОГО РЕЦЕПТОРА 9 (CCR9) И АНТИТЕЛАМИ, БЛОКИРУЮЩИМИ α4β7-ИНТЕГРИН | |
| NO20082297L (no) | Piperazinderivater som er anvendelige som CCR5-antagonister | |
| WO2012097238A3 (en) | Il-27 antagonists for treating inflammatory diseases | |
| JP2014521710A5 (ru) | ||
| MY181814A (en) | Pyrazolothiazole compound and medicine comprising same | |
| WO2015198217A3 (en) | Antibodies specific for il-17a fused to hyaluronan binding peptide tags | |
| JP2015527396A5 (ru) | ||
| Sabuncu et al. | Static and dynamic stability of cracked multi-storey steel frames | |
| WO2017106466A8 (en) | METHODS OF TREATING EXACERBATED INFLAMMATORY RESPONSE WITH TOPOISOMERASE l INHIBITORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20200926 |